低中收入国家COVID-19合并急性肾损伤的实用防治建议
该文针对低中收入国家(LMICs)资源受限场景,提出COVID-19合并急性肾损伤(AKI)的预防、诊断和管理实用建议。预防方面推荐使用等渗晶体液扩容、避免肾毒性药物、呼吸衰竭患者采用保守液体管理策略。诊断方面建议无历史值的血清肌酐升高即视为AKI,无肌酐检测时蛋白尿视为可能AKI,并建议在社区推广即时肌酐和唾液尿素氮检测。管理方面推荐审慎静脉液体复苏,需透析且无ARDS者首选腹膜透析,有ARDS者建议血液透析以优化液体清除,商业腹膜透析液不可得时使用本地生产腹膜透析液。
要点
- LMICs中COVID-19患者预防AKI:推荐使用等渗晶体液扩容、避免肾毒性药物、呼吸衰竭者采用保守液体管理策略。
- 诊断AKI:无历史血清肌酐值者,血清肌酐升高即视为AKI;无肌酐检测时,蛋白尿视为可能AKI。
- 建议在社区健康机构扩大即时血清肌酐和唾液尿素氮检测(视资金和可及性而定)。
- 需透析且无ARDS的COVID-19合并AKI患者:建议腹膜透析作为首选(条件是可及且可行)。
- 需透析且有ARDS的患者:建议血液透析以优化液体清除(条件是可及且可行)。
适用人群与场景
- 低中收入国家(LMICs)资源受限场景下的COVID-19合并急性肾损伤(AKI)患者。
诊断标准与关键阈值
- 无历史血清肌酐值的COVID-19患者,血清肌酐升高即视为AKI。
- 无血清肌酐检测条件时,蛋白尿视为可能AKI。
处置流程与药物剂量
- 预防AKI:使用等渗晶体液扩容血管内容量;避免肾毒性药物;呼吸衰竭患者采用保守液体管理策略。
- 诊断AKI:无历史肌酐值者血清肌酐升高即视为AKI;无肌酐检测时蛋白尿视为可能AKI;视资金和可及性在社区扩大即时血清肌酐和唾液尿素氮检测。
- AKI管理:审慎使用静脉液体复苏。
- 需透析且无ARDS:建议腹膜透析作为首选(可及且可行时)。
- 需透析且有ARDS:建议血液透析以优化液体清除(可及且可行时)。
- 商业腹膜透析液不可得或不可负担时:建议使用本地生产的腹膜透析液。
研究设计与关键结果
- 制定机构:未在摘要中明确;方法:未在摘要中描述;证据分级体系:未在摘要中描述。
证据类型、等级与局限
- 证据类型:指南(实用建议);推荐强度标签:推荐(recommend)用于预防AKI的等渗晶体液扩容、避免肾毒性药物、呼吸衰竭者保守液体管理及审慎静脉液体复苏;建议(suggest)用于无历史肌酐值者肌酐升高即视为AKI、无肌酐检测时蛋白尿视为可能AKI、扩大即时肌酐和唾液尿素氮检测、无ARDS者首选腹膜透析、有ARDS者血液透析、商业腹膜透析液不可得时使用本地生产腹膜透析液。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在LMICs资源受限场景下,对COVID-19患者预防AKI可遵循等渗晶体液扩容、避免肾毒性药物、呼吸衰竭者保守液体管理的推荐。
- 无历史肌酐值者血清肌酐升高即按AKI处理;无肌酐检测时蛋白尿视为可能AKI,可据此启动管理。
- 需透析的COVID-19合并AKI患者,无ARDS时建议首选腹膜透析,有ARDS时建议血液透析以优化液体清除(均需可及且可行)。
- 商业腹膜透析液不可得或不可负担时,建议使用本地生产的腹膜透析液。
指南或共识出处
- 指南名称:Pragmatic Recommendations for the Prevention and Treatment of Acute Kidney Injury in Patients with COVID-19 in Low- and Middle-Income Countries;发布机构:未在摘要中明确;年份:未在摘要中明确。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Current recommendations for the management of patients with COVID-19 and acute kidney injury (AKI) are largely based on evidence from resource-rich settings, mostly located in high-income countries. It is often unpractical to apply these recommendations to resource-restricted settings. We report on a set of pragmatic recommendations for the prevention, diagnosis, and management of patients with COVID-19 and AKI in low- and middle-income countries (LMICs). For the prevention of AKI among patients with COVID-19 in LMICs, we recommend using isotonic crystalloid solutions for expansion of intravascular volume, avoiding nephrotoxic medications, and using a conservative fluid management strategy in patients with respiratory failure. For the diagnosis of AKI, we suggest that any patient with COVID-19 presenting with an elevated serum creatinine level without available historical values be considered as having AKI. If serum creatinine testing is not available, we suggest that patients with proteinuria should be considered to have possible AKI. We suggest expansion of the use of point-of-care serum creatinine and salivary urea nitrogen testing in community health settings, as funding and availability allow. For the management of patients with AKI and COVID-19 in LMICS, we recommend judicious use of intravenous fluid resuscitation. For patients requiring dialysis who do not have acute respiratory distress syndrome (ARDS), we suggest using peritoneal dialysis (PD) as first choice, where available and feasible. For patients requiring dialysis who do have ARDS, we suggest using hemodialysis, where available and feasible, to optimize fluid removal. We suggest using locally produced PD solutions when commercially produced solutions are unavailable or unaffordable.
参考来源
- Rudd KE, Cizmeci EA, Galli GM, et al. Pragmatic Recommendations for the Prevention and Treatment of Acute Kidney Injury in Patients with COVID-19 in Low- and Middle-Income Countries. Am J Trop Med Hyg. 2021. PMID: 33432912. doi:10.4269/ajtmh.20-1242
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。